ESR1 and breast carcinoma: Model performance was evaluated by calculating the error of prediction of test set methylation, as shown for two examples in Fig. 4: oestrogen receptor 1 (ESR1) promoter in breast cancer (MSE=0.004; Fig. 4a); and androgen receptor (AR) promoter in prostate cancer (MSE=0.001; Fig. 4b).